Pre-emption Among Legal Hurdles For Triaminic Proposed Class Action
This article was originally published in The Tan Sheet
Executive Summary
A proposed class action alleging Novartis marketed pediatric cough/cold products that were ineffective and unsafe likely faces an uphill battle, according to industry attorneys including former FDA Chief Counsel Peter Barton Hutt